Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Common Equity (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Common Equity for 5 consecutive years, with $24.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 66.2% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.8 million through Dec 2025, down 66.2% year-over-year, with the annual reading at $24.8 million for FY2025, 66.2% down from the prior year.
  • Common Equity for Q4 2025 was $24.8 million at Werewolf Therapeutics, down from $29.6 million in the prior quarter.
  • The five-year high for Common Equity was $181.6 million in Q2 2021, with the low at -$153.8 million in Q1 2021.
  • Average Common Equity over 5 years is $93.7 million, with a median of $115.0 million recorded in 2023.
  • The sharpest move saw Common Equity surged 190.61% in 2022, then plummeted 66.87% in 2025.
  • Over 5 years, Common Equity stood at $152.8 million in 2021, then fell by 19.93% to $122.3 million in 2022, then decreased by 8.96% to $111.4 million in 2023, then crashed by 34.1% to $73.4 million in 2024, then plummeted by 66.2% to $24.8 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $24.8 million, $29.6 million, and $41.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.